Our Deals
Deals
Ancora acquired by Corden Pharma November 12, 2013
Overview
CordenPharma, an expert Contract Manufacturing partner helping leading pharmaceutical and biotechnology companies, announces its acquisition of Ancora Pharmaceuticals, Inc., a developer of immune system modulation therapeutics using synthetic carbohydrates.
CordenPharma provides specialized technologies that are ideal for the development and manufacturing of oral, sterile, highly potent and antibiotic pharmaceutical Drug Products, their Active Pharmaceutical Ingredients, and associated Global Supply Chain and Packaging Services.
Ancora develops glycoconjugate vaccines for the prevention of bacterial, fungal and parasitic infections.
Significance
CordenPharma will expand Ancora’s chemistry expertise into an organization that can provide scale and Current Good Manufacturing Practices (cGMP) manufacturing of complex synthetic carbohydrates.
Together, the companies will can provide a full range of carbohydrate synthesis and production needs, from early stage discovery research through to commercial cGMP manufacturing, at any scale, said Dr. Christian Ewers, Chief Operating Officer of CordenPharma’s API business.
Crosstree’s Role
Financial advisor to Ancora.